Skip to main content
. 2018 Aug 6;8:11739. doi: 10.1038/s41598-018-30168-4

Figure 4.

Figure 4

Influence of Coexpression of OCT4 and NANOG on Progression-Free Survival (PFS). PFS in renal cell carcinoma (RCC) patients (a), and PFS in clear cell renal cell carcinoma (ccRCC) patients (b). Patients with RCC (a) and ccRCC (b) showed worse PFS with high coexpression of nuclear OCT4 and nuclear NANOG in tumors.